157240-38-5

Upstream product

• 459-57-4 4-fluorobenzaldehyde 
• 136265-10-6 ethyl 4-fluorocinnamate 
• 459-32-5 (E)-4-fluorocinnamic acid 
• 1300036-08-1 C₁₂H₁₃FO₂ 
• 1300036-09-2 isopropyl (2R,3S)-3-acetylamino-2-hydroxy-3-(4-fluorophenyl)propionate 
• 154306-83-9 (3R,4S)-3-hydroxy-4-(4-fluorophenyl)-1-[(S)-1-phenyl]ethyl-2-azetidinone 
• 154306-84-0 methyl (2R,3S)-2-hydroxy-3-[(S)-1-phenyl]ethylamino-3-(4-fluorophenyl)propionate 

Downstream Products

• 1300036-11-6 N-de-tert-butoxycarbonyl-N-[2-(1-fluoro-2-methyl)propyloxycarbonyl]-7,10-di-(2,2,2-trichloroethyloxycarbonyl)-3-dephenyl-3'-(4-fluorophenyl)docetaxel 
• 1300036-12-7 N-de-tert-butoxycarbonyl-N-[2-(1,1-difluoro-2-methyl)propyloxycarbonyl]-7,10-di-(2,2,2-trichloroethyloxycarbonyl)-3-dephenyl-3'-(4-fluorophenyl)docetaxel 
• 1300036-13-8 N-de-tert-butoxycarbonyl-N-[2-(1,1,1-trifluoro-2-methyl)propyloxycarbonyl]-7,10-di-(2,2,2-trichloroethyloxycarbonyl)-3-dephenyl-3'-(4-fluorophenyl)docetaxel 
• 1300036-07-0 N-de-tert-butoxycarbonyl-N-[2-(1-fluoro-2-methyl)propyloxycarbonyl]-3-dephenyl-3'-(4-fluorophenyl)docetaxel 
• 1300036-14-9 N-de-tert-butoxycarbonyl-N-[2-(1,1-difluoro-2-methyl)propyloxycarbonyl]-3-dephenyl-3'-(4-fluorophenyl)docetaxel 
• 1300036-15-0 N-de-tert-butoxycarbonyl-N-[2-(1,1,1-trifluoro-2-methyl)propyloxycarbonyl]-3-dephenyl-3'-(4-fluorophenyl)docetaxel 
• 143527-63-3 C₅₂H₅₈Cl₆FNO₁₈ 
• 143527-60-0 C₄₉H₅₄Cl₆FNO₁₈ 
• 143527-61-1 3'-dephenyl-3'-(4-fluorophenyl)docetaxel 
• 143527-64-4 (4S,5R)-4-(4-Fluoro-phenyl)-2,2-dimethyl-oxazolidine-3,5-dicarboxylic acid 3-tert-butyl ester 
• 154306-86-2 (4S,5R)-4-(4-Fluoro-phenyl)-2,2-dimethyl-oxazolidine-3,5-dicarboxylic acid 3-tert-butyl ester 5-methyl ester 
• 154306-85-1 methyl (2R,3S)-3-tert-butoxy-carbonylamino-2-hydroxy-3-(4-fluorophenyl)propionate 

Relevant academic research and scientific papers

Synthesis, cytotoxicity, metabolic stability and pharmacokinetic evaluation of fluorinated docetaxel analogs

Three novel fluorinated docetaxel analogs, along with six previous reported, were evaluated for their cytotoxicity against five tumor cell lines. The results indicated that these analogs maintained similar/more potent activity than docetaxel against these tumor cell lines. They were also evaluated for their metabolic stability and pharmacokinetics, which demonstrated that these analogs showed better profiles of metabolic stability and pharmacokinetics than that of docetaxel.

Process for the preparation of β-phenylisoserine and β-lactam and their analogues

The present invention relates to new process for the preparation of β-phenylisoserine and its analogues of general formula: STR1 which are particularly useful for preparing taxane derivatives which have remarkable antitumour and antileukaemic activities.

Process for the preparation of β-phenylisoserine and its analogues

This invention relates to a method for preparing β-phenylisoserine and analogues thereof having general formula (I) STR1 from an aromatic aldehyde and an α-methylarylamine-S, and through a lactam of general formula (II) as described herein. The acids of g

A Practical Access to Chiral Phenylisoserinates, Preparation of Taxotere Analogs

A practical diastereoselective synthesis of phenylisoserine methyl esters 8a-c is described using α-methyl-benzylamine as the chiral template of a Staudinger reaction.Optically pure diastereoisomers 6a-c were easily recovered by crystallization.After opening of these intermediate azetidinones by hydrochloric acid and methanol, regioselective cleavage of the chiral auxiliary was achieved by hydrogenation over palladium.Phenylisoserinates 8b,c were used to prepare analogs of Taxotere.